Library Item - Page 17 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Posted by on Dec 30, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effects of carbohydrate-restricted diets and intermittent fasting (IF) in patients with obesity, type 2 diabetes (T2D), and hypertension (high blood pressure). The authors recommended that in adults with T2D, overweight or obesity, a moderately-low carbohydrate diet can be considered as a dietary...

Read More

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Posted by on Dec 30, 2022 in Hypertension | 0 comments

In a nutshell This study evaluated the effects of carbohydrate-restricted diets and intermittent fasting (IF) in patients with obesity, type 2 diabetes (T2D), and hypertension (high blood pressure). The authors recommended that in adults with T2D, overweight or obesity, a moderately-low carbohydrate diet can be considered as a dietary regimen for blood...

Read More

Does hyaluronic acid gel reduce intrauterine adhesions after surgery in women with miscarriage?

Does hyaluronic acid gel reduce intrauterine adhesions after surgery in women with miscarriage?

Posted by on Dec 30, 2022 in Infertility | 0 comments

In a nutshell This study evaluated whether hyaluronic acid gel (HAG) reduces intrauterine adhesions (IUAs) after curettage in women with a miscarriage. The data showed that HAG reduces the rate of IUAs in these women. Some background Up to a third of women who have a miscarriage need a dilation and curettage procedure for a miscarriage. A...

Read More

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...

Read More

Comparing the effectiveness of IVF/ICSI versus IUI in unexplained infertility

Comparing the effectiveness of IVF/ICSI versus IUI in unexplained infertility

Posted by on Dec 30, 2022 in Infertility | 0 comments

In a nutshell The study compared the pregnancy rates for intrauterine insemination (IUI) and in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) in couples with unexplained infertility. The data concluded that IVF/ICSI is a better treatment option than IUI for unexplained infertility. Some background Infertility is the inability to...

Read More

Evaluating the effectiveness of intralipid administration to improve in vitro fertilization outcomes

Evaluating the effectiveness of intralipid administration to improve in vitro fertilization outcomes

Posted by on Dec 9, 2022 in Infertility | 0 comments

In a nutshell The study evaluated the effectiveness of intralipid administration to improve in vitro fertilization (IVF) outcomes. The main finding was that injecting intralipid in women during IVF showed promising results in improving pregnancy and live birth rates. Some background Infertility is faced by many couples and IVF is one way to achieve...

Read More

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Posted by on Dec 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...

Read More

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Read More

Can icosapent ethyl prevent cardiovascular events and mortality in patients that have had previous heart attacks?

Can icosapent ethyl prevent cardiovascular events and mortality in patients that have had previous heart attacks?

Posted by on Dec 9, 2022 in Coronary artery disease | 0 comments

In a nutshell This study examined the effect of icosapent ethyl (IPE; Vascepa) on major cardiovascular events (MACEs) in statin-treated patients that had previous heart attacks (myocardial infarction; MI). The data showed that patients treated with IPE had large and significant reductions in MACEs. Some background Ischemic events are associated with a...

Read More

Evaluating the effectiveness of combining low-intensity extracorporeal shock wave therapy with vacuum erectile device for the treatment of patients with diabetes and erectile dysfunction.

Evaluating the effectiveness of combining low-intensity extracorporeal shock wave therapy with vacuum erectile device for the treatment of patients with diabetes and erectile dysfunction.

Posted by on Dec 4, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study evaluated the effectiveness of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with a vacuum erectile device (VED) for the treatment of patients with diabetes mellitus (DM) and erectile dysfunction (ED) who were unresponsive to phosphodiesterase-5 (PDE5) inhibitors. The data showed that Li-ESWT combined with...

Read More

Evaluating the effectiveness of combining low-intensity extracorporeal shock wave therapy with vacuum erectile device for the treatment of patients with diabetes and erectile dysfunction.

Evaluating the effectiveness of combining low-intensity extracorporeal shock wave therapy with vacuum erectile device for the treatment of patients with diabetes and erectile dysfunction.

Posted by on Dec 4, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with a vacuum erectile device (VED) for the treatment of patients with diabetes mellitus (DM) and erectile dysfunction (ED) who were unresponsive to phosphodiesterase-5 (PDE5) inhibitors. The data showed that Li-ESWT combined with...

Read More

Evaluating the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma ineligible for a transplant.

Evaluating the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma ineligible for a transplant.

Posted by on Dec 4, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma (MM) ineligible for a transplant. The data showed that first-line treatment should be based on daratumumab (Darzalex)-based regimens or the VRd regimen [bortezomib (V; Velcade), lenalidomide...

Read More